Know Cancer

or
forgot password

Iscar for Supplemental Care in Stage IV Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Iscar for Supplemental Care in Stage IV Lung Cancer


See Brief Summary


Inclusion Criteria:



- Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

- Known allergy to Viscum Album L.

- Concomitant use of other mistletoe products

- Concomitant use of mushroom glucan and proteoglycan extracts

- Concomitant use of thymus extract products

- Inability to self-report quality of life utilizing assessment tools

- Ongoing steroid or ACTH therapy

- Co-morbid immunocompromised state

- Pregnancy

- Participation in other clinical trials

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Steven Rosenzweig, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jefferson Medical College of Thomas Jefferson University

Authority:

United States: Food and Drug Administration

Study ID:

R21 AT001020-01

NCT ID:

NCT00079794

Start Date:

September 2001

Completion Date:

February 2004

Related Keywords:

  • Lung Cancer
  • lung cancer
  • herbal medicine
  • non-small cell cancer
  • Iscar
  • mistletoe
  • Lung Neoplasms

Name

Location

Thomas Jefferson UniversityPhiladelphia, Pennsylvania  19107-6541